Live prices from 83 UK suppliers, from £24.95, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Compare 1 price for Cagrilintide. Cheapest: £431.25. Average: £431.25.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
| £431.25 | £8.63/mg | In Stock | Free |
Lab Tested
|
— |
More ways to compare Cagrilintide
Different views of the same live UK pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination.
Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.
37-amino acid peptide
Phase 3 trials demonstrate significant weight loss.
22.7% weight loss with CagriSema combination, surpassing existing therapies.
15.7% weight loss in diabetic patients with concurrent glycemic improvements.
2.2% HbA1c reduction with CagriSema versus semaglutide alone.
Amylin receptor activation enhances insulin sensitivity and glucose metabolism.
Dual pathway satiety via amylin and calcitonin receptor activation.
Subcutaneous injection to abdomen, thigh, or upper arm. Pre-filled pen design when commercially available.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight Loss (Monotherapy) | 2.4mg | Once weekly | SubQ |
| Weight Loss (CagriSema) | 2.4mg + semaglutide 2.4mg | Once weekly | SubQ |
| Type 2 Diabetes Management | 2.4mg weekly | Once weekly | SubQ with metformin |
| Dose Escalation Protocol | 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg | Weekly increases over 16 weeks | SubQ |
CagriSema combination achieves enhanced weight loss through complementary GLP-1 and amylin pathways.
No known direct interactions; different mechanisms allow concurrent use.
Compounded GI side effects create substantial risk without specialist supervision.
Well-tolerated in Phase 2/3 trials with no pharmacokinetic interactions.
Clinical trials demonstrated safe concurrent use with complementary mechanisms.
Both are amylin agonists; combination provides no additional benefit and increases GI risks.
Delayed gastric emptying may affect absorption; space administration by 1 hour.
Gastrointestinal adaptation; mild nausea possible during dose escalation
Early weight loss (2-5%); noticeable appetite reduction
Significant weight loss acceleration (10-15%); improved satiety signals
Peak efficacy (15-23% weight loss); sustained maintenance with continued therapy
3,417 adults with obesity; 22.7% weight loss with CagriSema vs 2.4% placebo. New England Journal of Medicine.
1,206 adults; 15.7% weight loss; 73.5% achieved HbA1c ≤6.5%. New England Journal of Medicine.
32 weeks; 15.6% weight loss; 2.2% HbA1c reduction with CagriSema. The Lancet.
Plain-English guides and study summaries from published literature.
Guides
5 min
When retatrutide and cagrilintide are discussed together, the real issue is not only appetite control. It is also how to think about satiety, nutrition quality and lean-mass preservation.
Read article
Guides
5 min
Cagrilintide is often described as a peptide that supports satiety through the amylin pathway. Here is why that matters and why it is not just another GLP-1 conversation.
Read article
Guides
4 min
Retatrutide is often discussed as a powerful fat-loss peptide, but not always as the strongest appetite suppressant. Here is why cagrilintide keeps coming up in that conversation.
Read articleBe the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.